Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) known for its analgesic and anti-inflammatory properties. Understanding its interaction with biological targets at the molecular level is crucial for elucidating its therapeutic mechanisms and designing more effective derivatives. Molecular docking, a computational technique, offers insights into the binding modes and affinities of mefenamic acid with target proteins such as cyclooxygenases (COX) and other inflammatory mediators. This review provides an overview of recent advancements in molecular docking studies of mefenamic acid, highlighting its interactions with key residues within the active sites of target proteins. Furthermore, it discusses the implications of these findings for the development of novel mefenamic acid-based therapeutics with enhanced efficacy and reduced side effects.